Cat. No.: HY-13238A

Dolutegravir sodium

(Synonyms: S/GSK1349572 sodium)

35 Cited Publications

Customer Review

Based on 35 publication(s) in Google Scholar

Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM).

For research use only. We do not sell to patients.

Purity: 99.97%
CAS No.: 1051375-19-9
Formula: C₂₀H₁₈F₂N₃NaO₅
Molecular Weight:441.36

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Dolutegravir sodium Chemical Structure

CAS No.: 1051375-19-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (35)
Solvent & Solubility
- In Vitro
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

HIV-1

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
IM-9	CC₅₀	4.8 μM Compound: S/GSK-1349572	Cytotoxicity against human IM9 cells after 2 days by Cell titer Glo luminescent assay Cytotoxicity against human IM9 cells after 2 days by Cell titer Glo luminescent assay	[PMID: 21115794]
MOLT-4	CC₅₀	15 μM Compound: S/GSK-1349572	Cytotoxicity against human MOLT4 cells after 2 days by Cell titer Glo luminescent assay Cytotoxicity against human MOLT4 cells after 2 days by Cell titer Glo luminescent assay	[PMID: 21115794]
MT2	EC₅₀	0.26 nM Compound: S/GSK-1349572	Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 14 passages measured after 2 to 3 days by PCR Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 14 passages measured after 2 to 3 days by PCR	[PMID: 21115794]
MT2	EC₅₀	0.26 nM Compound: S/GSK-1349572	Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 28 passages measured after 2 to 3 days by PCR Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 28 passages measured after 2 to 3 days by PCR	[PMID: 21115794]
MT2	EC₅₀	0.26 nM Compound: S/GSK-1349572	Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 42 passages measured after 2 to 3 days by PCR Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 42 passages measured after 2 to 3 days by PCR	[PMID: 21115794]
MT2	EC₅₀	0.26 nM Compound: S/GSK-1349572	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect measured after 2 to 3 days by PCR Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect measured after 2 to 3 days by PCR	[PMID: 21115794]
MT2	EC₅₀	1.3 nM Compound: S/GSK-1349572	Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase S153Y/L101I/T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 112 passages measured after 2 to 3 da Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase S153Y/L101I/T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 112 passages measured after 2 to 3 da	[PMID: 21115794]
MT2	EC₅₀	1.3 nM Compound: S/GSK-1349572	Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase S153Y/L101I/T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 70 passages measured after 2 to 3 day Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase S153Y/L101I/T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 70 passages measured after 2 to 3 day	[PMID: 21115794]
MT2	EC₅₀	1.3 nM Compound: S/GSK-1349572	Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase S153Y/L101I/T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 84 passages measured after 2 to 3 day Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase S153Y/L101I/T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 84 passages measured after 2 to 3 day	[PMID: 21115794]
MT2	EC₅₀	1.3 nM Compound: S/GSK-1349572	Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase S153Y/L101I/T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 98 passages measured after 2 to 3 day Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase S153Y/L101I/T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 98 passages measured after 2 to 3 day	[PMID: 21115794]
MT2	EC₅₀	1.3 nM Compound: S/GSK-1349572	Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 56 passages measured after 2 to 3 days by PCR Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A/S153F mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 56 passages measured after 2 to 3 days by PCR	[PMID: 21115794]
MT4	CC₅₀	14 μM Compound: S/GSK-1349572	Cytotoxicity against human MT4 cells after 2 days by Cell titer Glo luminescent assay Cytotoxicity against human MT4 cells after 2 days by Cell titer Glo luminescent assay	[PMID: 21115794]
MT4	EC₅₀	0.36 nM Compound: S/GSK-1349572	Antiviral activity against PI-resistant Human immunodeficiency virus 1 NL432 harboring nucleotide reverse transcriptase L24I/M46I/L63P/A71V/G73S/V82Tmutant infected in human MT4 cells after 2 to 3 days by reverse transcriptase activity Antiviral activity against PI-resistant Human immunodeficiency virus 1 NL432 harboring nucleotide reverse transcriptase L24I/M46I/L63P/A71V/G73S/V82Tmutant infected in human MT4 cells after 2 to 3 days by reverse transcriptase activity	[PMID: 21115794]
MT4	EC₅₀	0.71 nM Compound: S/GSK-1349572	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as viral viability after 4 to 5 days by Cell titer Glo luminescent assay Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as viral viability after 4 to 5 days by Cell titer Glo luminescent assay	[PMID: 21115794]
PBMC	CC₅₀	189 μM Compound: S/GSK-1349572	Cytotoxicity against PHA-stimulated human PBMC after 2 days by Cell titer Glo luminescent assay Cytotoxicity against PHA-stimulated human PBMC after 2 days by Cell titer Glo luminescent assay	[PMID: 21115794]
PBMC	CC₅₀	52 μM Compound: S/GSK-1349572	Cytotoxicity against unstimulated human PBMC after 2 days by Cell titer Glo luminescent assay Cytotoxicity against unstimulated human PBMC after 2 days by Cell titer Glo luminescent assay	[PMID: 21115794]
U-937	CC₅₀	7 μM Compound: S/GSK-1349572	Cytotoxicity against human U937 cells after 2 days by Cell titer Glo luminescent assay Cytotoxicity against human U937 cells after 2 days by Cell titer Glo luminescent assay	[PMID: 21115794]

In Vitro

The EC₅₀ of Dolutegravir (S/GSK1349572) against HIV-1 is 0.51 nM in PBMCs, 0.71 nM in MT-4 cells, and 2.2 nM in the PHIV assay, which uses a pseudotyped self-inactivating virus. The 50% cytotoxic concentrations (CC₅₀) for Dolutegravir in proliferating IM-9, U-937, MT-4, and Molt-4 cells are 4.8, 7.0, 14, and 15 μM, respectively. In unstimulated and stimulated PBMCs, the CC₅₀ are 189 μM and 52 μM, respectively. Based on the EC₅₀ of Dolutegravir against HIV-1 in PBMCs (i.e., 0.51 nM), this translates to a cell-based therapeutic index of at least 9,400^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Following a single intravenous (IV) administration of Dolutegravir, the plasma clearance is low in rats (0.23?mL/min/kg) and monkeys (2.12?mL/min/kg). The half-lives in the rat and monkey are similar, approximately 6?h, and the steady-state volume of distribution (V_SS) is low. Following oral administration, Dolutegravir is rapidly absorbed with a high oral bioavailability when administered as a solution to fasted male rats and a single monkey (75.6 and 87.0%, respectively). Dolutegravir exposure (C_max and AUC) increased with increasing dose following oral administration of a suspension to non-fasted rats up to 250?mg/kg and non-fasted monkeys up to 50?mg/kg, although the increase is less than proportional^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1051375-19-9
Appearance Solid
Molecular Weight 441.36
Formula C₂₀H₁₈F₂N₃NaO₅
Color Off-white to yellow
SMILES

O=C(C1=CN(C2=C(O[Na])C1=O)C[C@]3([H])OCC[C@@H](C)N3C2=O)NCC4=CC=C(F)C=C4F
Synonyms

S/GSK1349572 sodium
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (35)

All Bio/Physico-chemical AssayCell Proliferation/Viability AssayRT-PCRCell Imaging/StainingELISAWB

Sort by:

Journal Impact Factor

Science

Structural basis of second-generation HIV integrase inhibitor action and viral resistance. [Abstract]

2020 Feb 14;367(6479):806-810. PMID: 32001525
Cell

Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo. [Abstract]

2025 Sep 4;188(18):4896-4912.e19. PMID: 40645177
Cell Rep Med

Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines. [Abstract]

2024 Sep 17;5(9):101702. PMID: 39216479
Cell Rep Med

Combination of compound screening with an animal model identifies pentamidine to prevent Chlamydia trachomatis infection. [Abstract]

2024 Jul 16;5(7):101643. PMID: 38981484

Dolutegravir sodium purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Jul 16;5(7):101643. [Abstract]

Dose-response curves for Dolutegravir (0.5-13.5 μM) against Ct serovars E, F, and L2. POC represented the percentage of DMSO-treated control.

Dolutegravir sodium purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Jul 16;5(7):101643. [Abstract]

Dolutegravir (13.5 μM) significantly blocked Ct growth in mice for genital chlamydia infection.
Sci Adv

Elucidating the mechanism by which HIV-1 nucleocapsid mutations confer resistance to integrase strand transfer inhibitors. [Abstract]

2025 Sep 12;11(37):eadz8980. PMID: 40938996

Dolutegravir sodium purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Sep 12;11(37):eadz8980. [Abstract]

Replication kinetics of the indicated NL4-3 variants of HIV-1 in the SupT1 T cell line in the absence or presence of Dolutegravir (DTG) (1-10 nM).
Biochem Pharmacol

Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function. [Abstract]

2024 Feb:220:116010. PMID: 38154544

Dolutegravir sodium purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2024 Feb:220:116010. [Abstract]

10 μM Dolutegravir (DTG) (1-10 μM) significantly repressed the mRNA expression levels of the adipocyte identity markers, peroxisome proliferator-activated receptor-gamma (PPARG) and lipoprotein lipase (LPL), as well as solute carrier family 2, facilitated glucose transporter member 4 (SLC2A4, GLUT4), and the adipokine, adiponectin (ADIPOQ), but induced that of solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1, GLUT1) and leptin (LEP) in SGBS human adipocytes.

Dolutegravir sodium purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2024 Feb:220:116010. [Abstract]

The effects of Dolutegravir (DTG) (1-10 μM) on the releases of leptin and adiponectin to the cell culture medium of differentiating SGBS human adipocytes are shown.
Life Sci

Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes. [Abstract]

2022 Nov 1:308:120948. PMID: 36096241
J Neuroimmune Pharmacol

Antiretroviral Drugs Promote Amyloidogenesis by De-Acidifying Endolysosomes. [Abstract]

2021 Mar;16(1):159-168. PMID: 31338753
Pharmaceuticals (Basel)

Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices. [Abstract]

2022 Feb 18;15(2):242. PMID: 35215354
Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744
ASN Neuro

Exposure to Frontline Antiretroviral Dolutegravir Disrupts Oligodendrocyte Development Across Differentiation Stages. [Abstract]

2026;18(1):2647877. PMID: 41904696
Antiviral Res

Differential effects of antiretroviral HIV integrase inhibitors on vascular cell adhesion molecules. [Abstract]

2025 Sep 11:106283. PMID: 40945692
FASEB J

Dolutegravir induces endoplasmic reticulum stress at the blood-brain barrier. [Abstract]

2025 Feb 28;39(4):e70377. PMID: 39985305
J Antimicrob Chemother

Cooperation between HIV-1 integrase natural polymorphism K156N and 3'PPT mutations in dolutegravir monotherapy failure. [Abstract]

2026 Feb 2;81(3):dkag033. PMID: 41636646
J Infect Dis

Second-generation HIV integrase inhibitors induce differentiation dysregulation and exert toxic effects in human embryonic stem cell and mouse models. [Abstract]

2022 Nov 28;226(11):1992-2001. PMID: 36124861
Anal Bioanal Chem

Development and validation of an LC-MS/MS assay for the quantification of dolutegravir extracted from human hair. [Abstract]

2018 Nov;410(29):7773-7781. PMID: 30280227
Open Forum Infect Dis

Novel Dolutegravir and Lenacapavir Resistance Patterns in Human Immunodeficiency Virus Type 2 Infection: A Case Report. [Abstract]

2024 Nov 29;12(1):ofae705. PMID: 39741997
Viruses

Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2. [Abstract]

2024 Oct 13;16(10):1607. PMID: 39459940
Viruses

Analysis and Molecular Determinants of HIV RNase H Cleavage Specificity at the PPT/U3 Junction. [Abstract]

2021 Jan 18;13(1):131. PMID: 33477685
Drug Metab Dispos

A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant Transporters. [Abstract]

2019 Jul;47(7):768-778. PMID: 31068368
Drug Metab Dispos

Mechanistic Assessment of Extrahepatic Contributions to Glucuronidation of Integrase Strand Transfer Inhibitors. [Abstract]

2019 May;47(5):535-544. PMID: 30804050
Toxicol Appl Pharmacol

The inhibitory effect of antiretroviral drugs on the L-carnitine uptake in human placenta. [Abstract]

2019 Apr 1:368:18-25. PMID: 30735677
Antivir Ther

Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence. [Abstract]

2017;22(8):645-657. PMID: 28350300

Dolutegravir sodium purchased from MedChemExpress. Usage Cited in: Antivir Ther. 2017;22(8):645-657. [Abstract]

Dolutegravir (DTG) and MVC+DTG significantly increase the SIRT1 level by respectively, 9% and 18%.
PLoS One

HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells. [Abstract]

2020 Jan 23;15(1):e0226924. PMID: 31971958
Biochem Biophys Res Commun

The inhibition process of HIV-1 integrase by diketoacids molecules: Understanding the factors governing the better efficiency of dolutegravir. [Abstract]

2017 Jul 1;488(3):433-438. PMID: 28478035
Cell Physiol Biochem

Enhanced Eryptosis Following Exposure to Dolutegravir. [Abstract]

2016;39(2):639-50. PMID: 27442249

Dolutegravir sodium purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2016;39(2):639-50. [Abstract]

Arithmetic means±SEM (n=19) of erythrocyte annexin-V-binding following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Dolutegravir (4.77-19.08 µM). For comparison, the effect of the solvent DMSO is shown (grey bar).
J Clin Pharmacol

Characterization of the Ontogeny of Hepatic UDP-Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes. [Abstract]

2019 Sep:59 Suppl 1:S42-S55. PMID: 31502688
STAR Protoc

Protocol to generate microglia-containing cerebral organoids to model HIV neuroinflammation. [Abstract]

2026 Jun 19;7(2):104604. PMID: 42224077
bioRxiv

2026 Apr 21.
University of Debrecen

2023.
Biomed Pharmacother

Differential adipose tissue remodeling and metabolic effects of dolutegravir and bictegravir: implications for HIV therapy. [Abstract]

2025 Dec:193:118831. PMID: 41317481
bioRxiv

Elucidating the Mechanism by Which HIV-1 Nucleocapsid Mutations Confer Resistance to Integrase Strand Transfer Inhibitors. [Abstract]

2025 May 18:2025.05.17.654662. PMID: 41030995
Res Sq

2024 May 24.
Preprints

2024 Apr 23.
PeerJ Physical Chemistry

2019, 1:e6.

Solvent & Solubility

In Vitro:

DMSO : 2 mg/mL (4.53 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2657 mL

11.3286 mL

22.6572 mL

5 mM

---

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Protocol

Cell Assay^[1]

In vitro growth inhibition (cytotoxicity) studies are conducted with S/GSK1349572 (0.16, 0.8, 4, and 20 nM) in proliferating human leukemic and lymphomic cell lines (IM-9, U-937, MT-4, and Molt-4) as well as in stimulated and unstimulated human PBMCs. ATP levels are quantified by using the CellTiter-Glo luciferase reagent to measure the ability of a compound to inhibit cell growth as an indicator of the compound's potential for cytotoxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

For rat and monkey PK studies, Dolutegravir is administered as the free acid or the sodium salt. All doses are presented in terms of the free acid. Dolutegravir is administered by intravenous (IV) short-term (within 2 min) bolus (1 mg/kg) to three male rats and two male monkeys. For single oral administration, Dolutegravir as a solution (5 mg/kg) is administered to three fasted male rats and two fasted male monkeys. Dolutegravir is administered as single oral doses of 5, 50, 100, and 250 mg/kg to non-fasted male rats (n=2/dose level) and 3, 10, and 50 mg/kg to non-fasted female monkeys. For intravenous administration, blood samples are collected from rats (0.2 mL via jugular vein cannula) and monkeys (approximately 0.2 or 0.5 mL via saphenous vein in a hindlimb) into Na₂EDTA-treated syringes at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h. For oral administration, samples are collected at 0.25 (rats only), 0.5, 1, 2, 4, 6 [rats (solution and suspension) and monkey (solution only)], 8, and 24 h. Following collection, the blood is immediately put on wet ice and then centrifuged within an hour at 1740 g for 10 min at 4°C to obtain plasma. All samples are stored at approximately -20°C or colder prior to analysis by using a method based on protein precipitation and LC-MS/MS analysis.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (398 KB)
- English - EN (398 KB)
- Français - FR (398 KB)
- Deutsch - DE (398 KB)
- Norwegian - NO (398 KB)
- Español - ES (398 KB)
- Swedish - SV (398 KB)
- Italian - IT (398 KB)
- Korean - KR (398 KB)
- Portuguese - PT (398 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Kobayashi M, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011 Feb;55(2):813-21. [Content Brief]

[2]. Moss L, et al. The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys. Xenobiotica. 2015 Jan;45(1):60-70. [Content Brief]

[3]. Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2657 mL	11.3286 mL	22.6572 mL	56.6431 mL

Keywords

Dolutegravir sodium

35 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Dolutegravir sodium

Raltegravir

Cabotegravir

Elvitegravir

Dolutegravir

Doravirine

Raltegravir potassium

BMS-707035

Dolutegravir (Standard)

Nelfinavir

Bictegravir sodium

Darunavir Ethanolate

Bictegravir

Publications Citing Use of MedChemExpress (MCE) Dolutegravir sodium

All HIV Isoforms

Biological Activity

Chemical Information

Publications (35)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Dolutegravir sodium

Raltegravir

Cabotegravir

Elvitegravir

Dolutegravir

Doravirine

Raltegravir potassium

BMS-707035

Dolutegravir (Standard)

Nelfinavir

Bictegravir sodium

Darunavir Ethanolate

Bictegravir

Publications Citing Use of MedChemExpress (MCE) Dolutegravir sodium

All HIV Isoforms

Biological Activity

Chemical Information

Publications (35)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Dolutegravir sodium Related Classifications

HY-13238A Related Classifications